Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies.
Bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy in cancer immunotherapy, enabling simultaneous targeting of two distinct antigens to redirect immune effector cells, block compensatory pathways, and modulate the tumor immune microenvironment (TIME). Hundreds of BsAbs are currently in clini...